96
Views
3
CrossRef citations to date
0
Altmetric
Research Letter

A nucleoside-sparing regimen of dolutegravir plus ritonavir-boosted atazanavir in HIV-1-infected patients with virological failure: the DOLATAV study

, , , , , , , , , & show all
Pages 477-479 | Published online: 24 Jan 2019
 

Acknowledgments

The authors should like to thank Editage for editing and reviewing this manuscript for English language usage. Bristol–Myers Squibb supported the study and provided ATV/r; ViiV Healthcare provided DTG.

Author contributions

VS conceived the study, followed the patients and wrote the first draft of the manuscript; AC conceived the study and reviewed and edited the manuscript; LG and AP performed statistical analyses and reviewed and edited the manuscript; DF and ML performed pharmacokinetic analyses and reviewed and edited the manuscript; AB, NG, SN, LF, and AL followed the patients and reviewed and edited the manuscript. All authors contributed to data analysis, drafting and revising the article, gave final approval of the version to be published, and agree to be accountable for all aspects of the work.

Disclosure

AC, AL, SN, and NG have received consultancy payments and speaking fee from Bristol–Myers Squibb, Gilead, ViiV Healthcare, Merck Sharp Dohme, Janssen. VS has received consultancy payments and speaking fee from Gilead, ViiV Healthcare and Janssen-Cilag. The authors report no other conflicts of interest in this work.